Comparative Study on the Effectiveness of Topical Recombinant Human Epidermal Growth Factor and Antibiotics on Herpes Zoster Skin Lesions
- Author:
Ji Hun PARK
1
;
Sun Gyu KIM
;
Se Uk OH
;
Ho Song KANG
;
Hyun-Min SEO
;
Joung Soo KIM
Author Information
1. Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2023;61(9):559-565
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Topical recombinant human epidermal growth factor (rhEGF) is effective in the treatment of diabetic foot ulcers, surgical wounds, burns, and scars. Binding of EGF to EGF receptors results in cell proliferation and differentiation.
Objective:This study aimed to evaluate the efficacy of topical rhEGF ointment compared with that of topical mupirocin in healing herpes zoster (HZ) lesions.
Methods:Thirty patients diagnosed with typical HZ were recruited in August, 2018. The rats were randomly divided into two groups: topical mupirocin and topical rhEGF ointment. HZ lesions were evaluated using the Vancouver Scar Scale (VSS) at the initial visit, 1st, 2nd, and 4th weeks.
Results:The total number of recruited patients (n=30) included males (n=16, 53.3%) and females (n=14, 46.7%) with a mean age of 58.2. The proportion of patients with a 50% reduction in the VSS score (VSS 50) at 2nd week was significantly higher in the rhEGF group (33.0% vs. 72.0%, respectively, p=0.035). The complete resolution rate (VSS=0, 1) at 4th week was also higher in the rhEGF group (17.5% vs. 50.0%, p=0.03).
Conclusion:Topical rhEGF showed a more rapid treatment response and anti-scarring effect than topical mupirocin in patients with HZ lesions.
